Literature DB >> 21698375

Practice variation in a longitudinal perspective: a multilevel analysis of the prescription of simvastatin in general practices between 2003 and 2009.

Henrik Ohlsson1, Marcia Vervloet, Liset van Dijk.   

Abstract

PURPOSE: The Dutch national guideline for Cardiovascular Risk Management advised in 2006 initiation of statin therapy in new patients with simvastatin. After the introduction of this guideline several measures were taken to increase the prescription of simvastatin in general practice. The aim of this paper is to describe the trend and interpractice variation in the relative share of simvastatin in statin prescription over a 7-year period (2003-2009) in Dutch general practices.
METHODS: Data were used from the National Registration Network of General Practice (LINH) in the Netherlands. We used multilevel logistic regression analysis with individuals nested within practices. We evaluated the variance at different time points by the intra-class correlation (ICC).
RESULTS: The share of simvastatin prescriptions of all statin prescriptions increased from 40% in 2003 to 82% in 2009. While the ICC was above 20% during the periods 2005 to 2007, it decreased rapidly from 25% in 2007 to only 9% in 2009.
CONCLUSION: Our results indicate that a combination of several intervention measures seems to have been successful. While it seems like the implementation of the guidelines alone had some effect, there was an additional effect when reimbursement measures were implemented. Furthermore, the practice seemed to have affected the adoption of the national CVRM guideline as the variation initially increased after the guideline implementation. By including information on both the proportion of simvastatin prescribed and interpractice variation, we achieved a more complete evaluation of how simvastatin prescription developed over time and how it was related to the different measures taken.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21698375     DOI: 10.1007/s00228-011-1082-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Multilevel analytical approaches in social epidemiology: measures of health variation compared with traditional measures of association.

Authors:  J Merlo
Journal:  J Epidemiol Community Health       Date:  2003-08       Impact factor: 3.710

2.  Impact of restricted reimbursement on the use of statins in Finland: a register-based study.

Authors:  Jaana E Martikainen; Leena K Saastamoinen; Maarit J Korhonen; Hannes Enlund; Arja Helin-Salmivaara
Journal:  Med Care       Date:  2010-09       Impact factor: 2.983

Review 3.  Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials.

Authors:  Paaladinesh Thavendiranathan; Akshay Bagai; M Alan Brookhart; Niteesh K Choudhry
Journal:  Arch Intern Med       Date:  2006-11-27

4.  Do guidelines create uniformity in medical practice?

Authors:  Judith D de Jong; Peter P Groenewegen; Peter Spreeuwenberg; François Schellevis; Gert P Westert
Journal:  Soc Sci Med       Date:  2009-10-29       Impact factor: 4.634

5.  Understanding adherence to therapeutic guidelines: a multilevel analysis of statin prescription in the Skaraborg Primary Care Database.

Authors:  Per Hjerpe; Henrik Ohlsson; Ulf Lindblad; Kristina Bengtsson Boström; Juan Merlo
Journal:  Eur J Clin Pharmacol       Date:  2010-12-29       Impact factor: 2.953

6.  Is the "practice style" hypothesis relevant for general practitioners? An analysis of antibiotics prescription for acute rhinopharyngitis.

Authors:  Julien Mousquès; Thomas Renaud; Olivier Scemama
Journal:  Soc Sci Med       Date:  2010-04       Impact factor: 4.634

7.  Variation in hospital length of stay: do physicians adapt their length of stay decisions to what is usual in the hospital where they work?

Authors:  Judith D de Jong; Gert P Westert; Ronald Lagoe; Peter P Groenewegen
Journal:  Health Serv Res       Date:  2006-04       Impact factor: 3.402

8.  Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.

Authors:  Helene M Devold; Espen Molden; Svetlana Skurtveit; Kari Furu
Journal:  Br J Clin Pharmacol       Date:  2009-02-09       Impact factor: 4.335

9.  Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.

Authors:  Devin Mann; Kristi Reynolds; Donald Smith; Paul Muntner
Journal:  Ann Pharmacother       Date:  2008-07-22       Impact factor: 3.154

10.  Understanding the effects of a decentralized budget on physicians' compliance with guidelines for statin prescription--a multilevel methodological approach.

Authors:  Henrik Ohlsson; Juan Merlo
Journal:  BMC Health Serv Res       Date:  2007-05-08       Impact factor: 2.655

View more
  4 in total

1.  Impact of remuneration on guideline adherence: empirical evidence in general practice.

Authors:  Christel E van Dijk; Robert A Verheij; P Spreeuwenberg; Michael J van den Berg; Peter P Groenewegen; Jozé Braspenning; Dinny H de Bakker
Journal:  Scand J Prim Health Care       Date:  2013-01-21       Impact factor: 2.581

2.  Impact of a Restriction in Reimbursement on Proton Pump Inhibitors in Patients with an Increased Risk of Gastric Complications.

Authors:  Linda E Flinterman; Karin Hek; Joke C Korevaar; Liset van Dijk
Journal:  Front Public Health       Date:  2018-02-27

3.  Prescribing and deprescribing antihypertensive medication in older people by Dutch general practitioners: a qualitative study.

Authors:  Tessa van Middelaar; Sophie D Ivens; Petra G van Peet; Rosalinde K E Poortvliet; Edo Richard; A Jeannette Pols; Eric P Moll van Charante
Journal:  BMJ Open       Date:  2018-04-20       Impact factor: 2.692

4.  Visualizing nationwide variation in medicare Part D prescribing patterns.

Authors:  Alexander Rosenberg; Christopher Fucile; Robert J White; Melissa Trayhan; Samir Farooq; Caroline M Quill; Lisa A Nelson; Samuel J Weisenthal; Kristen Bush; Martin S Zand
Journal:  BMC Med Inform Decis Mak       Date:  2018-11-19       Impact factor: 2.796

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.